AnnJi Pharmaceutical Co., Ltd. (7754.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$68.30 (-1.01%) as of
Key statistics
- Market cap
- 7.86B
- EPS (TTM)
- -4.21
- Dividend yield
- 0.00%
- 52-week range
- 39.20 – 86.00
- Beta
- -0.39
- Revenue (TTM)
- 959k
- Profit margin
- 0.00%
- Volume
- 260.97k
About AnnJi Pharmaceutical Co., Ltd.
AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis. AnnJi Pharmaceutical Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.